In a report released today, Michael Petusky from Barrington maintained a Buy rating on DENTSPLY SIRONA, with a price target of $14.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Michael Petusky has given his Buy rating due to a combination of factors that suggest potential upside for DENTSPLY SIRONA’s stock. The company’s shares are currently trading significantly below their historical highs, indicating a potential for recovery as market conditions improve. Petusky believes that much of the negative news has already been factored into the stock price, and the current valuation appears attractive, especially as tax loss selling diminishes.
Furthermore, the company’s strategic focus on accelerating R&D investments is expected to enhance product innovation, which could drive future growth despite short-term profitability challenges. Petusky anticipates a modest improvement in business performance, with the possibility of substantial gains if the company’s new leadership successfully addresses past underperformance issues. Additionally, favorable borrowing conditions for dental practices could support capital equipment purchases, further benefiting the company’s financial outlook. Consequently, Petusky maintains an OUTPERFORM rating with a price target of $14, reflecting confidence in the company’s long-term prospects.